All treatments
Treatment
Phesgo 600 mg/600 mg solution for injection clinical trials
2 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic confirmatory (Phase III)
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)
This study looks at new drug combinations for women with a certain type of aggressive breast cancer before surgery. It aims to see if these treatments can stop the cancer from coming back and improve long-term health, comparing their effects and safety.
For: Invasive Breast CancerSpain · Germany · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase IIIB, Multinational, Multicenter, Randomized, Open-Label Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administrationin Participants with Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer
This study looks at treating HER2-positive breast cancer. It compares giving a special medicine called Phesgo at home versus in the hospital to see which patients prefer. Researchers also check how well the treatment works and any side effects.
For: Early or Locally Advanced/ Inflammatory HER2-Positive Breast CancerSpain · Bulgaria · Croatia